Publications

Facilitating participation in clinical trials during pregnancy.

Vousden N. et al, (2023), BMJ, 380

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.

Chapman D. et al, (2023), Kidney Int

A Pragmatic Randomized Feasibility Trial of Influenza Vaccines

Johansen ND. et al, (2023), NEJM Evidence, 2

Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation.

Bowman L. et al, (2022), European heart journal

Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group None. et al, (2022), The New England journal of medicine

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet (London, England), 400, 1788 - 1801

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.

Staplin N. et al, (2022), Hypertension (Dallas, Tex. : 1979)

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet (London, England), 400, 832 - 845

Data provenance and integrity of health-care systems data for clinical trials.

Murray ML. et al, (2022), The Lancet. Digital health, 4, e567 - e568

Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.

Peto L. et al, (2022), Advances in biological regulation

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group None., (2022), Lancet (London, England), 400, 359 - 368

Allocated but not treated: the silent 16%

Horby P. et al, (2022), LANCET, 399, 1776 - 1776

Allocated but not treated: the silent 16% - Authors' reply.

Horby P. et al, (2022), Lancet (London, England), 399, 1775 - 1776

Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices).

Fraser AG. et al, (2022), European heart journal. Quality of care & clinical outcomes, 8, 249 - 258

Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting: Rationale and Design of the DANFLU-1 Trial

LANDRAY M., (2022), Pilot and Feasibility Studies

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), European heart journal, 43, 1416 - 1424

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

RECOVERY Collaborative Group None. et al, (2022)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2022), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet (London, England), 399, 665 - 676

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet (London, England), 399, 143 - 151

Cookies on this website

Publications